In the field of antiretroviral therapy, the combination of Tenofovir Disoproxil Fumarate, Efavirenz, and Emtricitabine stands as one of the most widely recommended regimens for the management of Human Immunodeficiency Virus (HIV-1) infection.
TELAVINCE EM, manufactured by Steris Healthcare Pvt. Ltd., is a scientifically formulated, single-tablet combination designed to deliver convenient, effective, and safe treatment to adults and adolescents living with HIV.
This advanced fixed-dose combination simplifies HIV management by offering three potent antiretroviral agents in a once-daily oral tablet, helping patients maintain viral suppression and enhance quality of life.
Composition
Each film-coated tablet of TELAVINCE EM contains:
Tenofovir Disoproxil Fumarate (TDF) – 300 mg
Emtricitabine – 200 mg
Efavirenz – 600 mg
These three ingredients work synergistically to prevent the replication and progression of HIV within the body.
What is TELAVINCE EM?
TELAVINCE EM is a fixed-dose combination antiretroviral therapy (ART) used for the treatment of HIV-1 infection in adults and adolescents aged 12 years and older.
By combining two nucleoside reverse transcriptase inhibitors (NRTIs) — Tenofovir Disoproxil Fumarate and Emtricitabine — with one non-nucleoside reverse transcriptase inhibitor (NNRTI) — Efavirenz — this formulation effectively inhibits the virus at multiple stages of its replication cycle.
It is primarily prescribed as first-line therapy and is included in many WHO-recommended HIV treatment guidelines due to its efficacy, tolerability, and convenience as a once-daily oral dose.
How TELAVINCE EM Works
TELAVINCE EM targets the core mechanism by which HIV multiplies — the action of reverse transcriptase, an enzyme responsible for converting viral RNA into DNA inside human cells.
Here’s how each component contributes:
🔹 Tenofovir Disoproxil Fumarate (TDF)
Acts as a nucleotide reverse transcriptase inhibitor (NtRTI).
Mimics the natural building blocks of DNA, causing premature termination of viral DNA synthesis.
Effectively reduces HIV replication and lowers viral load in the bloodstream.
🔹 Emtricitabine
A cytosine analogue and potent nucleoside reverse transcriptase inhibitor (NRTI).
Integrates into the viral DNA chain, blocking the enzyme responsible for replication.
Known for excellent tolerability and synergistic action with Tenofovir.
🔹 Efavirenz
A non-nucleoside reverse transcriptase inhibitor (NNRTI).
Binds directly to the reverse transcriptase enzyme, altering its shape and rendering it inactive.
Enhances overall viral suppression when used in combination with NRTIs.
Together, these mechanisms prevent the virus from multiplying, reduce the viral load, increase CD4 cell counts, and restore immune function — helping the patient maintain better health and reduce the risk of opportunistic infections.
Uses and Indications
TELAVINCE EM is primarily indicated for:
Treatment of HIV-1 infection in adults and adolescents aged 12 years and above.
First-line antiretroviral therapy in ART-naïve patients.
Can also be used in patients switching from other ART regimens with stable viral suppression under medical supervision.
By effectively controlling the virus, TELAVINCE EM prevents disease progression and reduces the risk of developing Acquired Immunodeficiency Syndrome (AIDS).
Key Benefits of TELAVINCE EM
Triple Action Formula: Three potent ARV agents in one tablet ensure comprehensive viral control.
Convenient Once-Daily Dose: Improves adherence and reduces pill burden.
Proven Efficacy: Demonstrated high success rates in achieving viral suppression and CD4 recovery.
Long-Term Tolerability: Clinically proven with manageable side effects under supervision.
Improves Quality of Life: Helps patients maintain active, healthy, and productive lives.
Reduces Transmission Risk: Lower viral load minimizes the risk of transmitting HIV to others.
Dosage and Administration
Recommended Dose: One tablet once daily at bedtime, preferably on an empty stomach to minimize side effects.
Administration: Swallow whole with water; do not crush or chew.
Duration: Continue as long as prescribed; discontinuation can cause viral rebound or resistance.
Note: Dosage adjustments may be required in patients with kidney impairment or in combination with certain other medications.
Possible Side Effects
Like all medications, TELAVINCE EM may cause side effects in some patients. Most are mild and temporary, especially during the first few weeks of treatment.
Common Side Effects:
Headache, dizziness, or insomnia
Nausea, vomiting, or diarrhea
Fatigue or loss of appetite
Mild skin rash or itching
Serious but Rare Side Effects:
Liver toxicity or hepatitis
Lactic acidosis (rare metabolic complication)
Kidney function impairment (especially with long-term Tenofovir use)
Depression or mood changes (related to Efavirenz)
Advice: Always report any severe or persistent symptoms to your healthcare provider immediately.
Precautions and Warnings
Avoid use if allergic to Tenofovir, Emtricitabine, or Efavirenz.
Regular liver and kidney function monitoring is recommended during therapy.
Avoid alcohol or recreational drugs that may intensify Efavirenz side effects.
Use with caution in patients with a history of psychiatric illness.
Pregnancy & Lactation: Use only if clearly prescribed by a doctor.
Do not stop treatment suddenly — it may lead to viral resistance or disease flare-up.
Drug Interactions
TELAVINCE EM may interact with:
Other antiretroviral medications – may require dose adjustment.
Anticonvulsants (phenytoin, carbamazepine) – may decrease Efavirenz levels.
Antifungal and antibiotic drugs – may alter drug metabolism.
St. John’s Wort – reduces efficacy of Efavirenz and should be avoided.
Always inform your doctor about all medications or supplements you are taking.
Storage Instructions
Store at room temperature (below 25°C) in a cool, dry place.
Keep away from direct sunlight and moisture.
Store out of reach of children.
Do not use after the expiry date mentioned on the pack.
Why Choose TELAVINCE EM from Steris Healthcare Pvt. Ltd.?
Steris Healthcare Pvt. Ltd. is one of India’s trusted pharmaceutical manufacturers committed to producing high-quality, affordable, and effective medicines that meet WHO-GMP standards.
Choosing TELAVINCE EM means choosing:
Assured Quality: Manufactured in state-of-the-art, WHO-GMP certified facilities.
Clinically Proven Efficacy: Formulated with precision for maximum therapeutic benefit.
Enhanced Patient Compliance: Single-tablet regimen for ease of use.
Nationwide Distribution: Available across India with reliable delivery.
Ethical & Patient-Centric Approach: Dedicated to improving patient well-being through innovation and care.
Conclusion
Tenofovir Disoproxil Fumarate, Efavirenz & Emtricitabine Tablets IP represents a cornerstone in the management of HIV-1 infection, offering powerful viral suppression, ease of use, and long-term safety.
Manufactured by Steris Healthcare Pvt. Ltd., this once-daily combination therapy ensures patients receive trusted quality, clinical efficacy, and affordability — enabling them to lead healthier, more confident lives.
FAQs
Q1. Can TELAVINCE EM cure HIV completely?
A1. No, TELAVINCE EM helps control the virus and maintain undetectable viral loads, but it does not cure HIV. Lifelong adherence is essential for viral suppression.
Q2. How long does it take for TELAVINCE EM to start working?
A2. Most patients experience a significant drop in viral load within 4 to 8 weeks of consistent therapy.
Q3. Can I stop taking TELAVINCE EM if I feel better?
A3. No, discontinuing treatment can cause viral rebound and resistance. Always follow your doctor’s advice.
Q4. Is TELAVINCE EM safe for long-term use?
A4. Yes, it is safe under regular medical supervision, with periodic monitoring of liver, kidney, and bone health.
Q5. Can TELAVINCE EM be taken with food?
A5. It’s best taken on an empty stomach at bedtime to minimize Efavirenz-related side effects like dizziness or vivid dreams.
